Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain

11/17/2017 | 01:08am EDT

Basel, 17 November 2017

Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain

  • The Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and augmenting data.
  • Executive, financial, operational, technical, and laboratory roles gain comprehensive insights, enabling data-driven decisions that improve laboratory processes and performance.
  • Viewics, Inc. will become an integral part of Roche and add further digital capabilities on top of Roche Diagnostics' Integrated Core Lab offering.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017. This acquisition allows Roche to expand its leading position in the Integrated Core Lab with business analytics capabilities, enabling laboratories to make faster data-driven informed decisions on their operations and processes. The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices (e.g. smart phones, tablets, desktop computers).

'We are excited that Viewics, Inc. will be joining the Roche Group, as it will help us to support our customers around the world in improving their lab performance and processes,' said Roland Diggelmann, CEO Roche Diagnostics. 'The Viewics solution offers our customers insights at their fingertips, uncovering potential value and profitability drivers in lab operations, and indicators to improve overall quality of care'.

'We founded Viewics with the belief that unlocking the value of data would drive immense value for our customers. With Roche's expertise and strong alignment within our teams, we are excited to embark on this next phase of Viewics' journey and jointly deliver on this mission,' said Dhiren Bhatia, Founder and President of Viewics, Inc.

'Viewics, Inc. strives to provide unprecedented access to disparate healthcare data to surface actionable insights and empower data-driven decision-making,' said Keith Laughman, CEO of Viewics, Inc. 'The Viewics platform generates insights that can inform real-time decisions about costs, laboratory performance, and many other areas affecting today's modern healthcare organizations. We are looking forward to working with our Roche colleagues in helping to support the lab's critical role in healthcare delivery.

The Viewics solution offers automated data extraction, cleansing, and augmentation architecture and resolves many of the typical problems that laboratory IT staff encounter when using generic business intelligence solutions, traditional data warehousing, or extraction methodologies.

About Viewics, Inc.

Viewics, Inc. was founded in 2010 in Sunnyvale, CA (USA) and is an established market player in business analytics for laboratories. The company, headquartered in San Jose, CA, has employees across the U.S. and in its subsidiary in Pune, India.

Through expertise and focus on healthcare analytics, Viewics, Inc. delivers proprietary, best-in-class technology for data extraction, cleansing, and transformation that quickly unlock insights, which deliver invaluable operational and financial outcomes, while reducing burden on IT.

The HIPAA-compliant solution puts the transformational power of analytics into the hands of healthcare professionals in laboratory, financial, executive, and IT roles. The solution enables organizations to leverage insights out-of-the-box, combined with the flexibility of further customising the solution to meet the needs of their unique situations, truly interact with their data and make decisions based on accurate information to deliver significant impact.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche Holding AG published this content on 17 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 November 2017 06:07:04 UTC.


© Publicnow 2017
All news about ROCHE HOLDING AG
09/17ROCHE : European Medicines Agency Recommends Roche's Lung Cancer Drug For Approv..
MT
09/17ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
09/17ROCHE : receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatm..
AQ
09/17PRESS RELEASE : Roche receives positive CHMP -2-
DJ
09/17PRESS RELEASE : Roche receives positive CHMP opinion for Gavreto(R) (pralsetinib..
DJ
09/17ROCHE : Drug Halts Tumor Proliferation in Mid-Stage Breast Cancer Study
MT
09/17ROCHE : presents first phase II data on giredestrant, a next generation selectiv..
PU
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/15ROCHE HOLDINGS AG : Receives a Buy rating from Deutsche Bank
MD
09/15ROCHE HOLDINGS AG : JP Morgan reaffirms its Neutral rating
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 302 M 65 734 M 65 734 M
Net income 2021 14 713 M 15 777 M 15 777 M
Net cash 2021 4 891 M 5 244 M 5 244 M
P/E ratio 2021 19,6x
Yield 2021 2,74%
Capitalization 299 B 321 B 321 B
EV / Sales 2021 4,80x
EV / Sales 2022 4,66x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 342,90 CHF
Average target price 384,23 CHF
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.97%321 442
JOHNSON & JOHNSON4.68%433 701
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604
ABBVIE INC.0.54%190 378